Across TCGA pan-cancer cohorts, BBOF1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BBOF1 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BBOF1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated BBOF1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.
BLCA, LIHC, and UCEC are the cancer types where BBOF1 Mutation most reproducibly stratifies survival.